PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Transplant Proc. Author manuscript; available in PMC 2010 November 5.
Published in final edited form as:
Transplant Proc. 1992 April; 24(2): 641.
PMCID: PMC2974303
NIHMSID: NIHMS242982

Long-Term Survival of Donor-Specific Pancreatic Islet Xenografts in Fully Xenogeneic Chimeras (F344 Rat to B10 Mouse)

The development of procedures to isolate large numbers of purified human pancreatic islet cells has made it possible to initiate a new phase of clinical trials in pancreatic islet transplantation for treatment of type 1 diabetes.1-3 Although nonspecific immunosuppressive agents have been instrumental in controlling alloreactivity to transplanted islet cells, rejection still occurs and is a major limitation to islet transplantation.4 The induction of donor-specific transplantation across a species barrier, using bone marrow stem cells to produce chimerism, has been suggested as a potential approach to prevent rejection of transplanted cells and overcome the shortage of available grafts. We recently reported that acceptance of donor-specific islet cell xenografts was achieved in fully xenogeneic chimeras (WF rat to B10 mouse) when WF rat (RtIAu) was the xenogeneic donor. To exclude a strain-specific effect, we have now evaluated whether similar tolerance would be present when F344 rat (RtIAl) was used as the xenogeneic donor. We report here that long-term acceptance and function of donor-specific (F344 rat) xenogeneic pancreatic islet grafts could be achieved in fully xenogeneic chimeras (B10 mouse + F344 rat to B10 mouse).

MATERIALS AND METHODS

Fully xenogeneic chimeras were prepared as previously described.5 Chimeras were made diabetic by a single intravenous injection of streptozotocin (165 mg/kg). Rat pancreatic islets were obtained and transplanted as previously reported.6

RESULTS AND DISCUSSION

After placement of either donor-specific F344 rat or third-party WF islet cell xenografts, normoglycemia occurred, indicating technical success. The survival of donor-specific F344 rat pancreatic islet xenografts was significantly prolonged (mean survival time [MST] 180 days; Fig 1). In contrast, major histocompatibility complex-disparate third-party WF rat islets were rapidly rejected, as evidenced by return of hyperglycemia (MST, 8 days). The donor-specific F344 grafts were functional to maintain the normoglycemic state in chimeras. This study demonstrates that long-term survival and function of donor-specific pancreatic islet xenografts could be obtained in fully xenogeneic chimeras and was not limited to a single strain as the xenogeneic donor.

Fig 1
Kinetics of blood glucose determination after streptozotocin, after placement of a donor-specific islet cell xenograft in fully xenogeneic chimera.

ACKNOWLEDGMENTS

The authors thank Michelle Waters for manuscript preparation, Richard James and Kathie Karr for technical assistance, and Marissa Mazzocchetti and Mary Oles for animal care.

Supported in part by the Juvenile Diabetes Foundation, National Institutes of Health Grant No. RO1 AI301 1501A1, the National Institutes of Health Shannon Award, and the American College of Surgeons Fellowship Award (199–1991).

REFERENCES

1. Scharp DW, Lacy PE, Santiago JV, et al. Transplantation. 1991;51:76. [PubMed]
2. Tzakis QAG, Ricordi C, Alejandro R, et al. Lancet. 1990;18:402. [PMC free article] [PubMed]
3. Scharp DW, Lacy PE, Santiago JC, et al. Diabetes. 1990;35:515. [PubMed]
4. Kahan B, Van Buren C, Bioleau M. Transplantation. 1983;35:9.
5. Ildstad ST, Wren SM, Boggs SS, et al. J Exp Med. 1991;8:467. [PMC free article] [PubMed]
6. Zeng Y, Ricordi C, Tzakis QAC, et al. Transplantation. in press.